A head-to-head trial of HexaBody-CD38 versus Darzalex Faspro revealed an overall response rate (ORR) of 55% and 52%, respectively, with Genmab pointing to "deeper responses" with the new drug and a ...

Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize ...

Mike Peters, of Dyserth, was admitted to The Christie hospital in Manchester in January. The father-of-two, who is married to Jules, has been undergoing Chimeric Antigen Receptor T-Cell Therapy (CAR-T ...

We recently compiled a list of the 10 Cash-Rich Undervalued Stocks To Invest In. In this article, we are going to take a look ...

The decision comes after Genmab provided J&J with data from a clinical proof-of-concept study, which included a head-to-head comparison with DARZALEX FASPRO® (daratumumab and hyaluronidase fihj) in ...

“With EPKINLY® (epcoritamab) moving from strength to strength and two wholly owned assets, rinatabart sesutecan (Rina-S™) and acasunlimab in Phase 3 development, we are confident in the ...

Despite the setback with HexaBody-CD38, van de Winkel highlighted the strength of EPKINLY® (epcoritamab) and two other assets, rinatabart sesutecan (Rina-S™) and acasunlimab, which are both in ...

On February 20, the company announced that Japan has approved EPKINLY (epcoritamab) to treat follicular lymphoma (FL) in patients who have already tried at least two other treatments. This makes ...

AbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed by epcoritamab, a bispecific antibody in development for non-Hodgkin’s lymphoma.